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Bacillus Calmette-Guérin (BCG) is a live attenuated strain of Mycobacterium bovis that has proven effective in the
treatment of early-stage bladder cancer. Although intravesical therapy with BCG is generally considered safe, serious
complications including hematuria, granulomatous pneumonitis, hepatitis, and life-threatening BCG sepsis are well
known. BCG-related vascular infections are rarely reported. We present a case of a ruptured abdominal aortic aneurysm
secondary toM bovis infection 2 years after intravesical instillation of BCG and review the related literature. ( J Vasc Surg
2007;46:131-4.)Bacillus Calmette-Guérin (BCG) is a live attenuated
strain of Mycobacterium bovis that was initially developed
for vaccination against tuberculosis. Since 1976, BCG has
been used as an effective treatment for early-stage transi-
tional carcinoma of the bladder, with reported cure rates of
70%.1 The mechanism of BCG antitumor activity is un-
known, but it likely involves a nonspecific stimulation of the
immune system that results in tumor cell death.2
BCG is generally considered safe, but it does have
known side effects, including fever (2.9%), hematuria (1%),
granulomatous pneumonitis/hepatitis (0.7%), and life-
threatening BCG sepsis (0.4%).3 M bovis infection of an
abdominal aortic aneurysm after BCG therapy is an ex-
tremely rare complication. We report a case of a ruptured
abdominal aortic aneurysm secondary to M bovis infection
after intravesical BCG therapy. The diagnosis was delayed 6
months because the aortic infection presented with non-
specific constitutional symptoms.
CASE REPORT
An 80-year-old man presented with a 6-month history of
fever, malaise, and a 30-pound weight loss. His past medical
history was significant for hypertension, chronic obstructive lung
disease, and a 55-pack-year smoking history. Two years before
presentation, he was diagnosed with a grade 1 transitional cell
carcinoma of the bladder that was treated with local resection and
six treatments of intravesical BCG.
Six months before his presentation at our center, he was
admitted to another institution for investigation of fever, anorexia,
and malaise. The working diagnosis was that of occult malignancy;
however, upper and lower gastrointestinal endoscopy, chest radi-
ography, bronchoscopy, and cystoscopy revealed no malignant
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also negative.
During the investigation, a chest and abdominal computed
tomography (CT) scan found 5.6-cm infrarenal aortic aneurysm
that did not show evidence of a mycotic process (Fig 1). In view of
his clinical presentation, the aneurysm was considered an asymp-
tomatic incidental finding. After a 3-week hospital admission, the
patient was discharged home with a tentative diagnosis of occult
malignancy. During the next 6 months, however, the patient
continued to deteriorate with increasing fever, malaise, and a
documented 30-pound weight loss.
He was admitted to the hospital once again for a work-up,
where he experienced a 2-hour episode of left lower back pain. A
repeat CT scan revealed the aneurysm size had increased to 7.6 cm
and had ruptured (Fig 2). The infrarenal neck was short (Fig 3).
The patient continued to be hemodynamically stable and was
transferred to our institution.
On arrival, the patient was in no distress, although visibly
cachectic. His pulse rate was 84 beats/min, blood pressure was
123/70 mm Hg, and he was afebrile. The chest and cardiovascular
examination were unremarkable. The abdominal examination re-
vealed a soft abdomen with a nontender pulsatile mass in the
midline. Laboratory results revealed a leukocyte count of 9.6/mL
and hemoglobin of 132 g/L.
In view of the fever, significant weight loss, and the sudden
increase in size of the aneurysm, the clinical presentation was
highly suggestive of a ruptured mycotic aneurysm. His prior treat-
ment with BCG combined with the 6-month history of malaise
raised concerns that BCG was the underlying etiology; therefore,
the patient was brought for urgent repair.
In consultation with the infectious disease service, preopera-
tive treatment with antituberculous therapy was not instituted
because of concerns of decreasing sensitivity of intraoperative
mycobacterial cultures. At operation, the aneurysm was juxtarenal
in location and unusual in appearance, with a gray color and
multiple lobulations on the anterior surface. There was edema in
the retroperitoneum but no dense inflammatory process or frank
purulence. Because of concern about the quantity and quality of
the juxtarenal aorta, the suprarenal aorta was dissected and the
renal arteries controlled with vascular loops (Fig 3). Intravenous
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clamped with distal clamping of the common iliac arteries.
On opening the aneurysm, there was evidence of chronic gray,
stringy, unusual appearing thrombus, although it was not frankly
purulent. Two large defects were present in the posterolateral
aortic wall, with extensive hematoma in the retroperitoneum con-
sistent with recent contained rupture. Before in situ replacement of
the aorta, the thrombus and aortic wall were extensively débrided
to remove as much infected tissue as possible, because we were still
not certain of the diagnosis and a bacterial source was still a
possibility. The aorta was then reconstructed with an infrarenal
18-mm  9-mm bifurcated Dacron graft soaked in rifampin (60
mg/mL) for 20 minutes before insertion.
The thrombus and aortic wall were sent for culture and
pathology. The clinical presentation and intraoperative findings
appeared consistent with a mycotic aneurysm most likely related to
Fig 1. Abdominal aortic aneurysm 6 months before treatment.
Fig 2. Ruptured mycotic abdominal aortic aneurysm just before
surgery.BCG. Antituberculous treatment with rifampin (600 mg, oncedaily) and isoniazid (300 mg, once daily) was started immediately
postoperatively.
Pneumonia developed postoperatively, which was treated with
intravenous antibiotics. The patient improved without incident.
Slowly, over 2 weeks, the patient was weaned from total parenteral
nutrition and tube feeding. In light of his poor nutrition, the
patient was discharged to a hospital in his own community for
further convalescence.
Permanent sections of the aortic wall showed a single granu-
loma, and Ziehl-Nielsen stain revealed curved bacilli consistent
with mycobacterial infection. Final acid-fast bacilli culture of the
aortic wall grew M bovis (BCG strain).
The patient is now 15 months from surgery and is doing well
clinically, living at home independently, and has no long-term
sequelae of his aneurysm repair. The antituberculous treatment
lasted 1year and has been discontinued on the recommendation of
the infectious disease service with suggestion for ongoing clinical
and CT follow-up.
DISCUSSION
Including the present case, only 13 cases of BCG-
related M bovis infection of the abdominal aorta have been
reported.4-14 In addition, there are another three cases of
large peripheral artery BCG-related infections,13,15,16 and
one aortic arch infection17 (Table). Similar to mycotic
aneurysms of any etiology, the triad of pulsatile mass, fever,
and abdominal pain was present in our patient. Unfortu-
nately, we are not certain whether this was an infection of a
pre-existing aortic aneurysm or the primary infection of a
normal aorta with subsequent aneurysm formation. How-
ever, the patient’s clinical risk factors of a long smoking
history, hypertension, and chronic obstructive lung disease
as well as his relatively unremarkable appearing aneurysm 6
months before rupture would suggest a pre-existing aneu-
rysm. Our patient had a protracted course of fever and
malaise and presented acutely with pain as a sign of rupture.
The mechanism of infection of the aorta is debated
Fig 3. Juxtarenal abdominal aorta.amongst authors and may represent either hematogenous
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retroperitoneum after instillation of BCG. The aorta can
also become infected after direct extension of the infective
process from a psoas abscess10,18 or osteomyelitis.14 How-
ever, one accepted risk factor for complications of BCG
therapy is urologic trauma at the time of treatment that
facilitates entry of the organism into the blood or lymphatic
systems. Our patient did have local resection of a bladder
tumor, but the timing of resection and BCG therapy is
unknown. Most authorities now recommend that BCG
therapy be delayed for several weeks after difficult bladder
catheterizations, cystitis, biopsy, or bladder resection to
minimize complications.19
The prevalence of aortic aneurysm in patients treated
with BCG is unknown and one would question whether
patients should be screened for aneurysms before treat-
ment. Most patients treated for bladder carcinoma would
likely have had abdominal ultrasound imaging or a CT scan
that would detect an aneurysm. It is unknown whether
patients with a known aortic aneurysm should receive pro-
phylactic antituberculous therapy before BCG instillation.
However, prophylactic treatment seems reasonable in all
patients who develop systemic reactions after BCG treat-
ment and in patients with new vascular prosthesis.11
The surgical management of tuberculous aneurysms
after BCG therapy has included débridement of the vessel
with extra-anatomic bypass (n  2)5,10 and in situ repair
with prosthetic graft (n  9) with good results4,6,7,9,11-14
(Table). One repair with an endovascular stent graft has
also been reported.8 This may become a reasonable alter-
native if the anatomy is suitable and we have personal
experience in the thoracic aorta with this. Unfortunately,
our patient’s juxtarenal anatomy would have made it a
Table. Review of all reported cases of mycotic aneurysm a
First author, year Age Sex Aneurysm
Woods,4 1988 62 F AA 
Bornet,15 1989 74 M Bi-FA 
Deresiewicz,5 1990 67 M AA 
Izes,17 1993 69 M Aortic arch 
Hellinger,6 1995 71 M AA 
Wolf,7 1995 80 M AA 
Rozenblit,8 1996 76 M AA 
Damm,9 1998 71 M AA 
LaBerge,10 1999 75 M AA 
Seelig,11 1999 58 M AA 
71 M AA
Kamphuis,12 2001 65 M AA 
Wada,13 2003 75 M Rt FA, AA 
Witjes,16 2003 67 M Popliteal 
Dahl,14 2005 69 M AA 
Present case, 2007 80 M AA
AA, Abdominal aorta; FA, femoral artery; AEF, aortoenteric fistula; MI, my
bypass.
*From bacille Calmette-Guérin therapy to treatment.difficult endovascular procedure.Standard management of primary aortic infection in-
volves extra-anatomic bypass, but in situ repair with a
prosthetic graft appears to be a safe treatment in the setting
of the relative low virulence of M bovis infection. Only one
recurrence with in situ replacement has been reported. This
patient was treated for a ruptured aortic aneurysm that, in
retrospect, was infected with M bovis and therefore received
no adjunctive antituberculous treatment for a 1-year
period.7 Conservative management with antituberculous
medical regime failed and an aortic-enteric fistula devel-
oped that required laparotomy and extra-anatomic bypass.
Therefore, if in situ prosthetic replacement is to be consid-
ered, long-term treatment with antituberculous chemo-
therapy is mandatory.
Mbovis is susceptible to isoniazid, rifampin, and etham-
butol, but is resistant to pyrazinamide.3 Although there is
no specific evidence to support this practice in the case of
tuberculous mycotic aneurysms, we and others have soaked
the Dacron graft in rifampin (60 mg/mL) before in situ
aortic reconstruction.20 In addition, gross contamination
such as occurs in aortoenteric fistula or extensive tubercu-
lous psoas abscess may preclude treatment with in situ
repair. Whenever in situ replacement is used, long-term
regular surveillance is required because infection of the
graft continues to be a concern.
CONCLUSION
Infection of an aortic aneurysm is a rare but serious
complication of BCG therapy. The diagnosis in our patient
was delayed by 6 months because his constitutional symp-
toms were misinterpreted as representing an occult malig-
nancy. Successful treatment therefore involves the recogni-
tion that all patients with prior BCG therapy and an
acille Calmette-Guérin therapy
Time lapse
(months)* Operation Outcome
17 In situ Survived
21 In situ Survived
14 E-A bypass Died
36 None Died
26 In situ Survived
24 In situ AEF
77 Stent graft, FF bypass Died of MI
7 In situ Survived
8 Stent graft
FF bypass
Recurrence
36 In situ Survived
48 In situ Survived
16 In situ Died
31 In situ Survived
18-21 None Survived
36-48 In situ Survived
24 In situ Survived
al infarction; E-A bypass, extra-anatomic bypass; F-F bypass, femorofemoralfter b
ocardianeurysm, especially presenting with fever or malaise, could
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ative cultures reveal a mycobacterial infection, we would
suggest prompt administration of preoperative antituber-
culous antibiotics. It appears from the published reports
that in situ reconstruction with a prosthetic graft is a safe
treatment, providing there is no gross contamination and
long-term antituberculous therapy is instituted. The appro-
priate duration of therapy is unclear, but 1 year appears to
be commonly recommended with clinical and CT follow-
up annually and probably biannually early on when recur-
rence rates will be highest.
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